Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

• Status: Completed
• Trial end date: 2013-05-09
• Target enrollment: 0
• Participant gender: All

Summary

This is a 36 week open-label extension of the canakinumab pre-filled syringe study for safety and tolerability in patients who have frequent flares of acute gouty arthritis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion criteria:

• Compliance and completion of the canakinumab PFS core study

• Unchanged significant clinical medical history from entry into core study

Exclusion criteria:

• Physician judgment of unsuitability for the study

• Pregnant or nursing women Other protocol-defined inclusion/exclusion criteria may apply